Weis Holger 4

What Happened

• Holger Weis, Chief Executive Officer of Alaunos Therapeutics, received 4,568 shares of common stock on July 23, 2026. The shares were valued at $1.92 each for a total of $8,771. This was an award/acquisition (not an open-market purchase or sale).

Key Details

• Transaction date and price: 7/23/2026 at $1.92 per share (4,568 shares; $8,771 total)
• Transaction type: A (award/grant/acquisition)
• Shares owned after transaction: Not disclosed in the provided filing excerpt
• Footnote: F1 — shares were issued in lieu of net salary (non-cash compensation)
• Filing timeliness: Report filed 7/27/2026; appears to be within the required two-business-day window

Context

• These shares were issued as compensation (salary in lieu) rather than a market purchase, so they primarily reflect pay structure rather than a direct market-buy signal. Such awards are routine for executives and do not, by themselves, indicate a change in insider sentiment.